Aurinia Pharmaceuticals: Funding, Investors & Team (Sep 2026)
Aurinia Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing and commercializing therapies to treat targeted patient populations that are suffering from serious diseases with a high unmet medical need. The company is currently developing voclosporin, an investigational drug, for the potential treatment of lupus nephritis, focal segmental glomerulosclerosis, and Dry Eye Syndrome.
Aurinia Pharmaceuticals has raised $3.1M across 1 funding round on record, the most recent an undisclosed round of $3.1M announced in Jun 2026.
That round is below the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Aurinia Pharmaceuticals Company Profile and Key Stats
Latest funding round on record: Jun 2026.
Aurinia Pharmaceuticals Funding Rounds
Aurinia Pharmaceuticals Founders and Leadership Team
No contact details are on record for this team yet.
Aurinia Pharmaceuticals Funding Compared to Other Biotechnology Startups
Aurinia Pharmaceuticals' latest round of $3.1M is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Aurinia Pharmaceuticals in Biotechnology and Victoria
Companies Similar to Aurinia Pharmaceuticals
Medicenna is a clinical-stage immunotherapy company focused on oncology and the development and…
Cybin is a clinical-stage biopharmaceutical company on a mission to create safe and effective…
Hemostemix Inc. is a Canadian biotechnology company that specializes in creating blood-derived cell therapies…
Avicanna is an organization in the biopharmaceutical sector that concentrates on enhancing medical cannabis…
Edesa Biotech is a privately-held company in the clinical stage that specializes in creating therapies for…
ME Therapeutics is a biotech company that specializes in finding and creating drugs for immuno-oncology that…
Medicus Pharma is a biotechnology research company that fast-tracks the progress of life sciences and…
ProteinQure is a biotechnology company specializing in creating innovative peptides for various medical…
Anodyne's mission is to create critical chemicals sustainably. Anodyne's approach takes advantage of nature's…
NervGen Pharma is a medicine company dedicated to creating solutions for the treatment of nerve damage and…
ZYUS is a biopharmaceutical company focused on providing patients with cannabinoids and other plant-based…
Resverlogix Corporation, a biopharmaceutical company, focuses on the development of novel therapeutics in…
Aurinia Pharmaceuticals Funding FAQs
What does Aurinia Pharmaceuticals do?
Aurinia Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing and commercializing therapies to treat targeted patient populations that are suffering from serious diseases with a high unmet medical need. The company is currently developing voclosporin, an investigational drug, for the potential treatment of lupus nephritis, focal segmental glomerulosclerosis, and Dry Eye Syndrome.
How much funding has Aurinia Pharmaceuticals raised?
Aurinia Pharmaceuticals has raised $3.1M across 1 round on record. The most recent is an undisclosed round of $3.1M announced in Jun 2026.
When did Aurinia Pharmaceuticals last raise funding?
Aurinia Pharmaceuticals' most recent funding round on record is an undisclosed round of $3.1M, announced in Jun 2026.
Who founded Aurinia Pharmaceuticals?
FundedIQ lists Michael Martin (Founder) at Aurinia Pharmaceuticals.
Where is Aurinia Pharmaceuticals headquartered?
Aurinia Pharmaceuticals is based in Victoria, British Columbia, Canada.
How many employees does Aurinia Pharmaceuticals have?
Aurinia Pharmaceuticals is in the 101-250 employee band.
How does Aurinia Pharmaceuticals' funding compare to other Biotechnology startups?
Aurinia Pharmaceuticals' latest round of $3.1M is below the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's Aurinia Pharmaceuticals Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Aurinia Pharmaceuticals is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.